Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Capital Expenditures (2023 - 2026)

Contineum Therapeutics' Capital Expenditures history spans 4 years, with the latest figure at $312000.0 for Q1 2026.

  • Quarterly Capital Expenditures rose 563.83% to $312000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $265000.0 through Mar 2026, down 35.99% year-over-year, with the annual reading at $514000.0 for FY2024, 1613.33% up from the prior year.
  • Capital Expenditures came in at $312000.0 for Q1 2026, up from -$189000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $312000.0 in Q1 2026 to a low of -$189000.0 in Q4 2025.
  • The 4-year median for Capital Expenditures is $52000.0 (2023), against an average of $65846.2.
  • Year-over-year, Capital Expenditures tumbled 213.86% in 2025 and then surged 563.83% in 2026.
  • Contineum Therapeutics' Capital Expenditures stood at -$75000.0 in 2023, then skyrocketed by 321.33% to $166000.0 in 2024, then crashed by 213.86% to -$189000.0 in 2025, then surged by 265.08% to $312000.0 in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Capital Expenditures are $312000.0 (Q1 2026), -$189000.0 (Q4 2025), and $98000.0 (Q3 2025).